Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase pseudogene 35 (GAPDHP35) is a processed pseudogene derived from the parent gene encoding the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Pseudogenes like GAPDHP35 are considered molecular fossils: they arise from gene duplication or retrotransposition events but have accumulated disabling mutations (such as frameshifts or stop codons) that prevent them from producing a functional protein. They are generally viewed as non-functional at the protein level and do not take part in metabolic pathways or cellular signaling. GAPDH pseudogenes are particularly abundant in the human genome, but most—including GAPDHP35—lack any direct biological activity. In rare cases, some pseudogenes can regulate the expression of their parent genes or participate in gene conversion events, but there is no evidence for such a role for GAPDHP35.
None (as a non-coding pseudogene, it does not serve as a direct drug target or have mechanisms of action)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 35 (GAPDHP35).